Jonathan Schneck

Immunotherapy relies on the manipulation of the immune system to induce a potent and durable attack on diseased cells. T cells play an integral role in this by directing immune responses against infected or cancerous cells. My laboratory uses biomaterials to induce natural T cell responses for personalized cancer immunotherapy. This includes development of nanoparticle-based artificial antigen presenting cells (aAPC) that activate tumor-specific T cells targeting multiple tumor-specific targets. These tumor-specific T cells can be reintroduced in a process called adoptive cell transfer (ACT), resulting in persistent anti-tumor activity with immunologic memory. With recent advances the our lab has made aAPC that can also be used to transfer genetic material, such as CAR constructs to T cells. Additionally, using biocompatible platforms, we have synthesized an artificial lymph node (aLN) capable of activating T cells in vivo.

Collectively, our interests’ and tools are synergistic with the “Foundational Pillars” and “Cross-Cutting” themes in TTEC’s strategic plan for “Adaptive Therapeutics”, which make him an excellent fit for TTEC.